TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38452310

Group type: EXPERIMENTAL
Intervention: Patient-driven genetic education webtool
Number of subjects: 315

Group type: COMPARATOR
Intervention: Genetic counseling (GC)
Number of subjects: 315
Study: 38452313

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38452327

Group type: EXPERIMENTAL
Intervention: Enzalutamide with talazoparib
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Enzalutamide with placebo
Number of subjects: 1035
Study: 38452496

Group type: EXPERIMENTAL
Intervention: Standard bilateral rTMS
Number of subjects: 164

Group type: COMPARATOR
Intervention: Bilateral theta burst stimulation (TBS)
Number of subjects: 164
Study: 38452779

Group type: EXPERIMENTAL
Intervention: Tafenoquine 300 mg (single dose)
Number of subjects: 5554

Group type: EXPERIMENTAL
Intervention: 7-day primaquine 0.5 mg/kg per day
Number of subjects: 5554

Group type: EXPERIMENTAL
Intervention: Weekly primaquine 0.75 mg/kg for 8 weeks
Number of subjects: 5554

Group type: COMPARATOR
Intervention: Tafenoquine (n=2134)
Number of subjects: 5554

Group type: COMPARATOR
Intervention: 7-day primaquine (n=370)
Number of subjects: 5554

Group type: COMPARATOR
Intervention: Tafenoquine
Number of subjects: 5554

Group type: COMPARATOR
Intervention: 7-day primaquine
Number of subjects: 5554
Study: 38452784

Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 253
Study: 38452788

Group type: EXPERIMENTAL
Intervention: ASTX727 (cedazuridine 100 mg and decitabine 35 mg) plus venetoclax 400 mg
Number of subjects: 62
Study: 38453176

Group type: EXPERIMENTAL
Intervention: Abemaciclib and letrozole
Number of subjects: 40
Study: 38453202

Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (12-week intervention comprising physical activity, nutrition, and breathing/relaxation delivered through a mobile application).
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention (12-week intervention).
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 88
Study: 38453208

Group type: EXPERIMENTAL
Intervention: Home-based mobile-guided exercise-based cardiac rehabilitation for 3 months
Number of subjects: 90
Study: 38453411

Group type: EXPERIMENTAL
Intervention: 2D measurements
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Whole-volume measurements
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Solid volume change measurements
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison of volumetric and 2D measurements
Number of subjects: 31
Study: 38453435

Group type: EXPERIMENTAL
Intervention: VS-505 2.25 g/day
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: VS-505 1.50 g/day
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: VS-505 4.50 g/day
Number of subjects: 158

Group type: COMPARATOR
Intervention: Sevelamer carbonate 4.80 g/day
Number of subjects: 158
Study: 38453677

Group type: COMPARATOR
Intervention: Vortioxetine (placebo-controlled, randomized, double-blind clinical trial)
Number of subjects: 144
Study: 38453781

Group type: EXPERIMENTAL
Intervention: TOP2A+ group received FEC100 for 3 cycles followed by 3 cycles of Trastuzumab (8 mg/kg then 6 mg/kg), Pertuzumab (840 mg/kg then 420 mg/kg), and Docetaxel (75 mg/m2).
Number of subjects: 74

Group type: COMPARATOR
Intervention: TOP2A- group received the same chemotherapy regimen as TOP2A+ group.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: TOP2A+ group received the same chemotherapy regimen as TOP2A- group.
Number of subjects: 74
Study: 38454079

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 278

Group type: COMPARATOR
Intervention: Switch to venlafaxine XR or duloxetine
Number of subjects: 278
Study: 38454126

Group type: EXPERIMENTAL
Intervention: IL-13Rα2-targeted CAR-T cells via dual ICT/ICV delivery
Number of subjects: 65
Study: 38454132

Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 292
Study: 38454421

Group type: EXPERIMENTAL
Intervention: Stable plaques
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Unstable plaques
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Validation group (immunohistochemistry analysis)
Number of subjects: 182
Study: 38454451

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus gemcitabine and oxaliplatin (GEMOX)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus GEMOX
Number of subjects: 42
Study: 38454468

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) - five cycles every other day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham apheresis (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 66
Study: 38454482

Group type: EXPERIMENTAL
Intervention: Functional DNase levels in severe patients
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DNase1 antigen levels
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DNase1L3 antigen levels
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DNASE1 polymorphisms
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Plasmacytoid dendritic cells (pDCs)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: DNase administration
Number of subjects: 145
Study: 38454501

Group type: EXPERIMENTAL
Intervention: SEARCH-IPT intervention (collaborative groups of district health managers, leadership and management training over 3 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard practice (control group)
Number of subjects: 0
Study: 38455033

Group type: EXPERIMENTAL
Intervention: Blended preconception lifestyle programme (PreLiFe-programme) including a mobile application with tailored advice and skills training on diet, physical activity, and mindfulness, combined with motivational interviewing over the telephone.
Number of subjects: 211

Group type: COMPARATOR
Intervention: Attention control arm receiving treatment information by mobile phone in addition to standard care.
Number of subjects: 211
Study: 38455366

Group type: EXPERIMENTAL
Intervention: Hemay022 at doses of 50-600 mg QD and 300 mg BID
Number of subjects: 28
Study: 38455850

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg tablets, three times per day (total dose of 1500 mg/day) for eight weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38455935

Group type: EXPERIMENTAL
Intervention: Cross-sectional survey with questionnaire and physical measurements
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Biological, genetic and microbiological analyses
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Collection of genomic data combined with anthropological data
Number of subjects: 2100
Study: 38455948

Group type: EXPERIMENTAL
Intervention: Post-discharge risk prediction algorithms for mother-newborn dyads
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Prediction models for maternal outcomes
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Prediction models for newborn outcomes
Number of subjects: 7000
Study: 38456042

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment linkage strategies
Number of subjects: 0
Study: 38456291

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (2 × 12 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 50
Study: 38456289

Group type: EXPERIMENTAL
Intervention: Comprehensive speckle-tracking echocardiography with passive leg raise maneuver
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Arterial stiffness assessment
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Proteomics (including NT-proBNP)
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Echocardiographic indices
Number of subjects: 3285
Study: 38456441

Group type: EXPERIMENTAL
Intervention: Accu-Chek Solo micropump system (Solo)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Multiple Daily Injections (MDI)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Omnipod
Number of subjects: 181
Study: 38456438

Group type: EXPERIMENTAL
Intervention: hs-cTnT (high-sensitivity cardiac troponin T) levels
Number of subjects: 385
Study: 38456561

Group type: EXPERIMENTAL
Intervention: 40-minute immersive simulation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Online educational training (control)
Number of subjects: 40
Study: 38456620

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 332
Study: 38456636

Group type: EXPERIMENTAL
Intervention: Education program (individual four face-to-face and six online education sessions)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 52
Study: 38456660

Group type: EXPERIMENTAL
Intervention: Navitoclax (250 mg daily days 1 to 28) and Trametinib (2 mg daily days 1 to 14)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Navitoclax and Trametinib
Number of subjects: 91
Study: 38456703

Group type: EXPERIMENTAL
Intervention: Triple-dose CoronaVac
Number of subjects: 55

Group type: COMPARATOR
Intervention: Unvaccinated individuals
Number of subjects: 55
Study: 38456705

Group type: EXPERIMENTAL
Intervention: PCV20
Number of subjects: 1204

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1204
Study: 38456874

Group type: EXPERIMENTAL
Intervention: Discharge GDMT prescription after CABG surgery
Number of subjects: 968

Group type: COMPARATOR
Intervention: Discharge GDMT prescription
Number of subjects: 968
Study: 38456888

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) deactivated in a home setting and reactivated when pain returned.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) with back pain as primary indication, high-frequency stimulation, and higher pain score at deactivation.
Number of subjects: 158
Study: 38456933

Group type: EXPERIMENTAL
Intervention: Dragon Boat activity
Number of subjects: 31

Group type: COMPARATOR
Intervention: Home-based non-supervised training program (Control)
Number of subjects: 31
Study: 38457041

Group type: EXPERIMENTAL
Intervention: Single hem-o-lok clips
Number of subjects: 294

Group type: COMPARATOR
Intervention: Double hem-o-lok clips
Number of subjects: 294
Study: 38457151

Group type: EXPERIMENTAL
Intervention: Gait-prioritization (GP) strategy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Manual-prioritization (MP) strategy
Number of subjects: 34
Study: 38457175

Group type: EXPERIMENTAL
Intervention: Postoperative experiences after mastectomy (including lymphedema, phantom breast sensations, persistent chronic pain, changes in body image and sexuality)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Postoperative experiences after mastectomy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Information about sexuality from healthcare professionals
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Follow-up period after mastectomy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Nurse-patient dialogue regarding hospitalization and sexuality
Number of subjects: 23
Study: 38457177

Group type: EXPERIMENTAL
Intervention: Folic acid-fortified iodized salt (300 µg/d of folic acid)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 83
Study: 38457203

Group type: EXPERIMENTAL
Intervention: Opioid Management for You (OPY) tool - social influence version
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid Management for You (OPY) tool - precommitment version
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioid Management for You (OPY) tool - testimonial version
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 38457202

Group type: EXPERIMENTAL
Intervention: Suubi-Mhealth intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 38457361

Group type: EXPERIMENTAL
Intervention: NL-ratio (neutrophil-to-lymphocytes ratio) > 2.44
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: NL-ratio (tenth decile > 3.53)
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: ML-ratio (monocytes-to-lymphocytes ratio) (tenth decile > 2.02)
Number of subjects: 1022
Study: 38457359

Group type: EXPERIMENTAL
Intervention: MRD <0.1% at end of induction (EOI)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: MRD ≥0.1% at end of induction (EOI)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Cox regression for EFS using arm A as reference
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 209
Study: 38457759

Group type: EXPERIMENTAL
Intervention: Lugol's chromoendoscopy (screening group)
Number of subjects: 33847

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 33847
Study: 38457761

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 559

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 559
Study: 38458016

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention consisting of weekly one-hour sessions combining heart rate variability and temperature biofeedback for six weeks.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 20
Study: 38458039

Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group A (PIK3CA alterations)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group B (cell cycle pathway alterations)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group C (no druggable genetic alterations)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group A
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group B
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Durvalumab (immune checkpoint inhibitor) in Group C
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Lower neutrophil-lymphocyte ratio (NLR) (≤5.8)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Lower platelet-lymphocyte ratio (PLR) (≤491.2)
Number of subjects: 87
Study: 38458089

Group type: EXPERIMENTAL
Intervention: Tailored health literacy follow-up from MI-trained COPD nurses with home visits for eight weeks and phone calls for four months after hospitalization
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Tailored health literacy follow-up from MI-trained COPD nurses
Number of subjects: 127
Study: 38458208

Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Paracetamol plus dexamethasone
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus dexamethasone
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Paracetamol plus ibuprofen plus dexamethasone
Number of subjects: 1060
Study: 38458318

Group type: EXPERIMENTAL
Intervention: Caregiver and child depression and anxiety measures
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Asthma control assessed by the Asthma Control Test
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 205
Study: 38458362

Group type: EXPERIMENTAL
Intervention: 1-step conservative surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1-step conservative surgery (subgroup type 1 class)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hysterectomy (subgroup type 1 class)
Number of subjects: 60
Study: 38458371

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 489

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 489
Study: 38458387

Group type: EXPERIMENTAL
Intervention: Maximum preoperative diameter of the abdominal aorta >30 mm and/or abdominal aortic dissection
Number of subjects: 990

Group type: COMPARATOR
Intervention: No maximum diameter >30 mm and no abdominal aortic dissection
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Maximum preoperative diameter of the abdominal aorta
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Abdominal aorta dissection
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Genetic syndromes
Number of subjects: 990
Study: 38458408

Group type: EXPERIMENTAL
Intervention: Double etonogestrel implant (136 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Single etonogestrel implant (68 mg)
Number of subjects: 72
Study: 38458558

Group type: EXPERIMENTAL
Intervention: EPIC intervention (telephonic, geriatrics-palliative care nurse-coaching)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual COPD care (control)
Number of subjects: 60
Study: 38458560

Group type: EXPERIMENTAL
Intervention: Healthy Food Delivery Intervention (HFDI) plus one 60-min virtual consultation with a diabetes educator
Number of subjects: 400

Group type: COMPARATOR
Intervention: Consultation only
Number of subjects: 400
Study: 38458577

Group type: EXPERIMENTAL
Intervention: 200 g cooked iron-fortified lentils (IFLs)
Number of subjects: 1195

Group type: COMPARATOR
Intervention: 200 g cooked noniron-fortified lentils (NIFLs)
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Control group with no lentils (usual dietary intake)
Number of subjects: 1195
Study: 38458584

Group type: EXPERIMENTAL
Intervention: Postoperative ischemic stroke
Number of subjects: 3902

Group type: EXPERIMENTAL
Intervention: Postoperative hemorrhagic stroke
Number of subjects: 3902

Group type: EXPERIMENTAL
Intervention: Global brain ischemia
Number of subjects: 3902

Group type: COMPARATOR
Intervention: No neurologic complications
Number of subjects: 3902
Study: 38458635

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) combined with PD-1 inhibitor toripalimab
Number of subjects: 21
Study: 38458639

Group type: EXPERIMENTAL
Intervention: urelumab-0.1 + cetuximab-250
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: urelumab-3 + nivolumab-3
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: urelumab-8 + nivolumab-3
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: urelumab-8 + nivolumab-240
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: urelumab + nivolumab
Number of subjects: 200
Study: 38458769

Group type: COMPARATOR
Intervention: systolic flow reversal ratio (sFRR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: average late systolic flow displacement (FD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: manual systolic rotational flow angle change (ΔsRA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: average systolic FD (FDsavg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: ΔsRA
Number of subjects: 15
Study: 38458783

Group type: EXPERIMENTAL
Intervention: Revealed screening with sFlt-1/PlGF ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concealed screening (unknown sFlt-1/PlGF ratio)
Number of subjects: 0
Study: 38458786

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) with health education
Number of subjects: 256

Group type: COMPARATOR
Intervention: Superficial acupuncture (SA) with health education
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 256
Study: 38458788

Group type: EXPERIMENTAL
Intervention: Clinical KOA at baseline
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Visceral fat area (VFA)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Worse knee pain intensity
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: KOOS Pain score
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: KOOS Symptoms score
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: KOOS Activities of daily living score
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: KOOS Quality of Life score
Number of subjects: 178
Study: 38458796

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antihypertensive medicines (AHT)
Number of subjects: 0
Study: 38458811

Group type: EXPERIMENTAL
Intervention: Management of long bone fractures and traumatic hip dislocations in paediatric patients
Number of subjects: 750
Study: 38458816

Group type: EXPERIMENTAL
Intervention: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor, GM-CSF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor)
Number of subjects: 60
Study: 38459049

Group type: EXPERIMENTAL
Intervention: Regular care with additional videoconference consultations (VCG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Regular care group (RCG)
Number of subjects: 56
Study: 38459072

Group type: EXPERIMENTAL
Intervention: S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vaccine (1790GAHB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38459156

Group type: EXPERIMENTAL
Intervention: R-GemOx (Rituximab, gemcitabine, and oxaliplatin)
Number of subjects: 55
Study: 38459160

Group type: EXPERIMENTAL
Intervention: MiniMed 780G
Number of subjects: 29
Study: 38459254

Group type: EXPERIMENTAL
Intervention: Spurs and build-ups (SBU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spurs only (S)
Number of subjects: 0
Study: 38459338

Group type: EXPERIMENTAL
Intervention: INS018_055 (small-molecule TNIK inhibitor)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 38459353

Group type: EXPERIMENTAL
Intervention: Dating Matters intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard of care intervention
Number of subjects: 46
Study: 38459510

Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: 16D
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Comparison of HRQoL by condition
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Correlation between PedsQL and 16D
Number of subjects: 512